Entering text into the input field will update the search result below

Biota Pharma's BTA585 Fast Track'd for RSV infections

Feb. 16, 2016 10:43 AM ETVaxart, Inc. (VXRT) StockBy: Douglas W. House, SA News Editor
  • The FDA designates Biota Pharmaceuticals' (BOTA +10.6%) antiviral candidate, BTA585, for Fast Track review for the treatment of respiratory syncytial virus (RSV) infections. RSV is a major cause of upper and lower respiratory tract infections in infants, children and young adults.
  • BTA585 is an oral RSV fusion inhibitor that fights RSV infection by interfering with the fusion of the viral envelope to the cell membrane of the host cell.
  • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).

Recommended For You

More Trending News

About VXRT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VXRT--
Vaxart, Inc.